Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Dec 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-12-28

Reporting Person: Hogge Gary S. (SVP,Clinical & Medical Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-28	Common Shares, no par value	M	185000	$0.6919	Acquired	213445	Direct
2021-12-28	Common Shares, no par value	M	236899	$2.11	Acquired	450344	Direct
2021-12-28	Common Shares, no par value	M	79689	$1.14	Acquired	530033	Direct
2021-12-28	Common Shares, no par value	S	501588	$2.45	Disposed	28445	Direct
2021-12-29	Common Shares, no par value	M	9250	$0.6919	Acquired	37695	Direct
2021-12-29	Common Shares, no par value	S	9250	$2.49	Disposed	28445	Direct
2021-12-29	Common Shares, no par value	S	28445	$2.44	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-28	Employee Stock Option (right to buy)	$0.6919	M	185000	Disposed	2030-03-17	Common Shares (185000)	Direct
2021-12-28	Employee Stock Option (right to buy)	$2.11	M	236899	Disposed	2028-02-11	Common Shares (236899)	Direct
2021-12-28	Employee Stock Option (right to buy)	$1.14	M	79689	Disposed	2029-02-12	Common Shares (79689)	Direct
2021-12-29	Employee Stock Option (right to buy)	$0.6919	M	9250	Disposed	2030-03-17	Common Shares (9250)	Direct

Footnotes

F1: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.40 to not more than $2.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2: The 9,250 shares sold on 12/29/21, were all sold at a transaction price of $2.49.

F3: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.42 to not more than $2.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F4: The reporting person was granted options on March 17, 2020, with an exercise price of $0.6919 per share to purchase up to 444,000 common shares of the issuer. One quarter of the options vested and became exercisable on March 17, 2021, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.

F5: The reporting person was granted options on February 11, 2018, with an exercise price of $2.11 per share to purchase up to 247,200 common shares of the issuer. One quarter of the options vested and became exercisable on February 11, 2019, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.

F6: The reporting person was granted options on February 12, 2019, with an exercise price of $1.14 per share to purchase up to 112,500 common shares of the issuer. One quarter of the options vested and became exercisable on February 12, 2020, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.